DDInter1008 DDInter1400
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Ketoconazole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pazopanib
Ketoconazole {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Ketoconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Pazopanib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Ketoconazole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pazopanib
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is downregulated by {v} (Disease) and {u} (Disease) associated with {v} (Gene) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Ketoconazole {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is regulated by {v} (Gene) CSF1R
CSF1R {u} (Gene) is bound by {v} (Compound) Pazopanib
Ketoconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Ketoconazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Ketoconazole (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is upregulated by Pazopanib (Compound)
Ketoconazole (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Pazopanib (Compound)
Ketoconazole (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Ketoconazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is downregulated by kidney cancer (Disease) and ABCB1 (Disease) associated with kidney cancer (Gene) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Ketoconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is downregulated by Pazopanib (Compound)
Ketoconazole (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is regulated by CSF1R (Gene) and CSF1R (Gene) is bound by Pazopanib (Compound)
Ketoconazole (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Fluconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib